PV-10 Data on Locoregional Disease Control in Metastatic Melanoma to Be Presented at European Cancer
PV-10 Data on Locoregional Disease Control in Metastatic Melanoma to Be Presented at European Cancer Congress 2013
Poster Presentation on September 30, 2013
KNOXVILLE, TN--(BUSINESS WIRE)-- Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that an exploratory analysis of data on locoregional disease control in metastatic melanoma from its completed Phase 2 study of intralesional PV-10 has been accepted for presentation at the upcoming European Cancer Congress (ECCO 17- ESMO-38 - ESTRO 32), which will take place September 27 through October 1, 2013 in Amsterdam, The Netherlands.
Provectus's PV-10, a 10% solution of Rose Bengal that is currently being examined as a novel cancer therapeutic, is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, and significantly reduce the potential for systemic side effects. The Phase 2 study of melanoma patients looked at the effect of intralesional (IL) injection of PV-10 on selective ablation of injected lesions and for tumor-specific, immune-mediated bystander response in untreated lesions in which T cells are implicated.
The data to be presented at ECCO is based on Abstract No. 3.755, entitled, "Locoregional Disease Control in Metastatic Melanoma: Exploratory Analysis From Phase 2 Testing of Intralesional Rose Bengal," authored by S.S. Agarwala, J.F. Thompson, B.M. Smithers, M.I. Ross, B.J. Coventry, D.R. Minor, C.R. Scoggins, J. M. Singer and E.A. Wachter.
Sanjiv S. Agarwala, MD, Principal Investigator for the Phase 2 trial of PV-10, and Chief of Medical Oncology and Hematology at St. Luke's Hospital and Health Network in Bethlehem, PA, will deliver the presentation during the Poster Session on "Melanoma and Skin Cancer" which is scheduled for Monday, September 30, 2013 from 9:30 a.m. to 12:00 noon.
Craig Dees, Ph.D., CEO of Provectus Pharmaceuticals said, "We are honored to have our research on PV-10's potential use in the control and management of metastatic melanoma accepted for inclusion at this important event. ECCO is the premier European cancer research organization known for its truly multidisciplinary approach to fighting cancer. We believe that PV-10 has the potential to become a valuable weapon in the expanding arsenal clinicians and their patients need to fight and conquer this devastating disease."
As founding members of ECCO - the European CanCer Organisation, ESMO, ESTRO, ESSO, EACR, EONS and SIOPE, have joined together once again to form a powerful combination of seven senior organisations endorsing multidisciplinarity as the way forward to best improve the prevention, diagnosis, treatment and care of cancer patients.
Our renowned biennial series of multidisciplinary European Cancer Congresses are recognized as the premier cancer meetings in Europe. At Stockholm in 2011, 15,931 participants from all disciplines experienced the strongest and most forward-focused scientific programme to date.
The 17th ECCO - 38th ESMO - 32nd ESTRO European Cancer Congress being held in Amsterdam, September 27 - October 1, 2013, will once again combine the united efforts of all partner organisations to continue positioning multidisciplinarity as the way forward to best improve the prevention, diagnosis, treatment and care of cancer patients. The recognized multidisciplinary setting of the Congress will provide ideal surroundings for participants to leverage knowledge, promote education and build awareness about oncology - placing the patient at the heart of all our efforts and discussions.
About Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.
Provectus Pharmaceuticals, Inc.
Peter R. Culpepper, 866-594-5999 #30
Porter, LeVay & Rose, Inc.
Marlon Nurse, DM, SVP - Investor Relations
Bill Gordon, SVP - Media Relations
KEYWORDS: United States North America Tennessee
The article PV-10 Data on Locoregional Disease Control in Metastatic Melanoma to Be Presented at European Cancer Congress 2013 originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.